文献速递淋巴瘤造血干细胞移植与细胞治疗

同种异体即用型CAR T细胞疗法治疗复发或难治性B细胞恶性肿瘤

Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies.
PubMed 文献 · Blood Adv · 2025-01-01

本研究开发了基于EBV特异性T细胞(EBV-VSTs)经CD19特异性CAR(19-28z)基因修饰的同种异体「即用型」CAR T细胞产品。16例复发/难治性B细胞恶性肿瘤患者分入3个队列,主要目的为评估多次CAR EBV-VST输注的安全性。未发生严重细胞因子释放综合征或神经毒性,未观察到剂量限制性毒性;中位随访48个月,12个月总生存率81%,36个月总生存率75%。

要点

  • 3×10^6 T细胞/kg为最佳剂量,可支持同一制造细胞系多次治疗。
  • 未发生严重细胞因子释放综合征或神经毒性,未观察到剂量限制性毒性。
  • 中位随访48个月,12个月总生存率81%,36个月总生存率75%。

核心结论

  • 本研究证明同种异体「即用型」CAR EBV-VST产品在CD19+复发/难治性B细胞恶性肿瘤患者中具有可行性和安全性,并取得良好结局。

研究设计与样本

  • 本研究为临床试验,采用EBV特异性T细胞经CD19特异性CAR(19-28z)基因修饰的同种异体「即用型」CAR T细胞产品。
  • 患者为复发/难治性B细胞恶性肿瘤,分为3个治疗队列:队列1(n=8;同种异体或自体造血细胞移植后疾病复发)、队列2(n=6;自体造血细胞移植后巩固治疗)、队列3(n=2;同种异体造血细胞移植后巩固治疗)。
  • 主要目的为确定多次CAR EBV-VST输注的安全性;试验注册号NCT01430390。

主要发现

  • 多数患者(n=12/16)接受了多次剂量(总体中位数2.5,范围1-3),确定3×10^6 T细胞/kg为最佳剂量,可支持同一制造细胞系多次治疗。
  • 输注后未发生严重细胞因子释放综合征或神经毒性,试验中未观察到剂量限制性毒性。
  • 中位随访48个月(范围4-135),4例死亡归因于疾病进展。
  • 所有患者12个月总生存率为81%,36个月总生存率为75%。
  • 输注后扩增和持久性有限,CAR EBV-VSTs与自体19-28z CAR T细胞相比表现出独特的T细胞表型。

局限性

  • 输注后扩增和持久性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite clinical benefit with the use of chimeric antigen receptor (CAR) T cells, the need to manufacture patient-specific products limits its clinical utility. To overcome this barrier, we developed an allogeneic "off-the-shelf" CAR T-cell product using Epstein-Barr virus (EBV)-specific T cells (EBV-VSTs) genetically modified with a CD19-specific CAR (19-28z). Patients with relapsed/refractory (R/R) B-cell malignancies were stratified into 3 treatment cohorts: cohort 1 (n = 8; disease recurrence after allogeneic or autologous hematopoietic cell transplantation [HCT]), cohort 2 (n = 6; consolidative therapy after autologous HCT), or cohort 3 (n = 2; consolidative therapy after allogeneic HCT). The primary objective of this trial was to determine the safety of multiple CAR EBV-VST infusions. Most patients (n = 12/16) received multiple doses (overall median, 2.5 [range, 1-3]) with 3 × 106 T cells per kg determined to be the optimal dose enabling multiple treatments per manufactured cell line. Severe cytokine release syndrome or neurotoxicity did not occur after infusion, and no dose-limiting toxicity was observed in the trial. Median follow-up was 48 months (range, 4-135) with 4 deaths due to disease progression. Overall survival of all patients was 81% at 12 months and 75% at 36 months. Postinfusion expansion and persistence were limited, and CAR EBV-VSTs demonstrated a unique T-cell phenotype compared with autologous 19-28z CAR T cells. Our study demonstrates the feasibility and safety of an allogeneic "off-the-shelf" CAR EBV-VST product with favorable outcomes for patients with CD19+ R/R B-cell malignancies. This trial was registered at www.ClinicalTrials.gov as #NCT01430390.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shahid S, Prockop SE, Flynn GC, et al. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. Blood Adv. 2025. PMID: 39908482. doi:10.1182/bloodadvances.2024015157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。